More Neurizon Therapeutics Limited news
Neurizon Therapeutics LimitedASX: NUZ

Appendix 4C - Quarterly Report & Shareholders Update

Jan 30, 2018 at 10:32 PM EST · Issued by Neurizon Therapeutics Limited

Filed with ASX · Jan 30, 2018 at 10:32 PM EST · 9 pages · English

On 6ix: 6ix.com/news/appendix-4c-quarterly-report-and-shareholders-update

Neurizon Therapeutics Limited on 6ix

Story so far

  • Appendix 4C - Quarterly Report & Brief Company UpdateOct 26, 2017
  • Appendix 4C - Quarterly Report & Company Update - March 2017Apr 13, 2017
  • Appendix 4C - Quarterly Report & Company UpdateJan 31, 2017

Earlier from Neurizon Therapeutics

  • Monepantel reformulation successfully improves dose & tasteJan 29, 2018
  • Epichem Awarded One Year Contract Extension from DNDiJan 17, 2018
  • Phase II Dog Lymphoma Trial Confirms MPL Clinical BenefitDec 12, 2017
  • PharmAust Raises $1.873m via an Oversubscribed PlacementDec 5, 2017
  • New MPL analogues show greater anti-cancer activityNov 22, 2017

Later from Neurizon Therapeutics

  • PharmAust receives $354k R&D Tax Incentive RefundFeb 27, 2018
  • Appendix 4D and Half Yearly Report & AccountsFeb 28, 2018
  • PharmAust enters option to license agreement with ElancoApr 18, 2018
  • Appendix 4C & Company UpdateApr 30, 2018
  • Chief Executive Officer resignsMay 21, 2018
All Neurizon Therapeutics news releases↗

Follow Neurizon Therapeutics into a list and get an email when it puts out news.

Follow Neurizon Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer